Clinical and preclinical data suggest that acute myeloid leukemia (AML) with mutated nucleophosmin 1 ( NPM1 mut) might constitute an immunogenic leukemia subtype. In general, AML with NPM1 mut correlates with better prognosis, but the underlying mechanisms still remain to be elucidated. Our group
No takes yet. Share an insight, caveat, or question.
Greiner et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: